Loading
SPOP (Speckle-type POZ protein) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Prostate cancer, Endometrial cancer, Non-Hodgkin lymphoma and 4 more. This dossier gathers the 0 products (0 approved), 0 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
Component of a cullin-RING-based BCR (BTB-CUL3-RBX1) E3 ubiquitin-protein ligase complex that mediates the ubiquitination of target proteins, leading most often to their proteasomal degradation. In complex with CUL3, involved in ubiquitination and proteasomal degradation of BRMS1, DAXX, PDX1/IPF1, GLI2 and GLI3. In complex with CUL3, involved in ubiquitination of MACROH2A1 and BMI1; this does not lead to their proteasomal degradation. Inhibits transcriptional activation of PDX1/IPF1 targets, such as insulin, by promoting PDX1/IPF1 degradation. The cullin-RING-based BCR (BTB-CUL3-RBX1) E3 ubiquitin-protein ligase complex containing homodimeric SPOP has higher ubiquitin ligase activity than the complex that contains the heterodimer formed by SPOP and SPOPL. Involved in the regulation of bromodomain and extra-terminal motif (BET) proteins BRD2, BRD3, BRD4 stability. Location: Nucleus; Nucleus speckle; Cytoplasm (UniProt). Locus 17q21.33 (HGNC).
| Cancer | Prevalence | Measure | Note | Source |
|---|---|---|---|---|
| Prostate cancer | 6-14% | Missense mutation in the substrate-binding cleft | cBioPortal: 318 of 2,260, 14.1%, in prostate_msk_2024; 260 of 2,069, 12.6%, in prad_msk_stopsack_2021; 166 of 1,465, 11.3%, in prad_cdk12_mskcc_2020; 55 of 494, 11.1%, in prad_tcga_pan_can_atlas_2018 and 37 of 333, 11.1%, in prad_tcga_pub; 14 of 112, 12.5%, in prad_broad; 53 of 424, 12.5%, in prad_mcspc_mskcc_2020; 92 of 1,013, 9.1%, in prad_p1000; 38 of 477, 8.0%, in prad_cpcg_2017; 25 of 444, 5.6%, in prad_su2c_2019; 11 of 65, 16.9%, in prad_eururol_2017. The discovery series put it at 6 to 15% across several independent cohorts (Barbieri 2012). | cBioPortal (TCGA) |
Approximate, population-level figures; the measure column says what was counted. Ranges show the midpoint as a bar.
No product in the corpus is aimed at this target yet.
No trial in the corpus names this target or one of its products.
No recorded escape route names this target.
No pathway diagram carries this target as a node.
No companion diagnostic in the registry measures this target.
No model entry for this target yet; check the cancer entries on the models page.
No open questions recorded for this target yet. Suggest one.
Query for this target: (TITLE:"SPOP" OR ABSTRACT:"SPOP" OR TITLE:"speckle type BTB/POZ protein" OR ABSTRACT:"speckle type BTB/POZ protein" OR TITLE:"Speckle-type POZ protein" OR ABSTRACT:"Speckle-type POZ protein" OR TITLE:"TEF2" OR ABSTRACT:"TEF2" OR TITLE:"BTBD32" OR ABSTRACT:"BTBD32") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about SPOP, not a curated reading list.
The dossier as machine-readable JSON, at /api/v1/dossiers/spop.json: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/spop.json. Licence CC BY-NC 4.0.